These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 38363395)

  • 1. Identification of Potentially Repurposable Drugs for Lewy Body Dementia Using a Network-Based Approach.
    Manoj M; Sowmyanarayan S; Kowshik AV; Chatterjee J
    J Mol Neurosci; 2024 Feb; 74(1):21. PubMed ID: 38363395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacotherapy of dementia with Lewy bodies.
    Fernandez HH; Wu CK; Ott BR
    Expert Opin Pharmacother; 2003 Nov; 4(11):2027-37. PubMed ID: 14596656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
    Rolinski M; Fox C; Maidment I; McShane R
    Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD006504. PubMed ID: 22419314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Lewy body dementia: therapeutic propositions according to evidence based medicine and practice].
    Verny M; Blanc F
    Geriatr Psychol Neuropsychiatr Vieil; 2019 Jun; 17(2):189-197. PubMed ID: 31162119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A soluble tau fragment generated by caspase-2 is associated with dementia in Lewy body disease.
    Smith BR; Nelson KM; Kemper LJ; Leinonen-Wright K; Petersen A; Keene CD; Ashe KH
    Acta Neuropathol Commun; 2019 Jul; 7(1):124. PubMed ID: 31362787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Therapies and Drug Development Pipeline in Lewy Body Dementia: An Update.
    MacDonald S; Shah AS; Tousi B
    Drugs Aging; 2022 Jul; 39(7):505-522. PubMed ID: 35619045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pinpointing novel risk loci for Lewy body dementia and the shared genetic etiology with Alzheimer's disease and Parkinson's disease: a large-scale multi-trait association analysis.
    Guo P; Gong W; Li Y; Liu L; Yan R; Wang Y; Zhang Y; Yuan Z
    BMC Med; 2022 Jun; 20(1):214. PubMed ID: 35729600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffuse Lewy body disease presenting as Parkinson's disease with progressive aphasia.
    Koga S; Murakami A; Josephs KA; Dickson DW
    Neuropathology; 2022 Feb; 42(1):82-89. PubMed ID: 35029300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dementia with Lewy bodies: emerging drug targets and therapeutics.
    Pope ED; Cordes L; Shi J; Mari Z; Decourt B; Sabbagh MN
    Expert Opin Investig Drugs; 2021 Jun; 30(6):603-609. PubMed ID: 33899637
    [No Abstract]   [Full Text] [Related]  

  • 10. Other Antidepressants.
    Schwasinger-Schmidt TE; Macaluso M
    Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex differences for clinical correlates of substantia nigra neuron loss in people with Lewy body pathology.
    Bayram E; Coughlin DG; Rajmohan R; Litvan I
    Biol Sex Differ; 2024 Jan; 15(1):8. PubMed ID: 38243325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.
    Jellinger KA
    J Neural Transm (Vienna); 2018 Apr; 125(4):615-650. PubMed ID: 29222591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study.
    Williams DR; Lees AJ
    Lancet Neurol; 2005 Oct; 4(10):605-10. PubMed ID: 16168928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis.
    Wang HF; Yu JT; Tang SW; Jiang T; Tan CC; Meng XF; Wang C; Tan MS; Tan L
    J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):135-43. PubMed ID: 24828899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LRP10 interacts with SORL1 in the intracellular vesicle trafficking pathway in non-neuronal brain cells and localises to Lewy bodies in Parkinson's disease and dementia with Lewy bodies.
    Grochowska MM; Carreras Mascaro A; Boumeester V; Natale D; Breedveld GJ; Geut H; van Cappellen WA; Boon AJW; Kievit AJA; Sammler E; ; Parchi P; Cortelli P; Alessi DR; van de Berg WDJ; Bonifati V; Mandemakers W
    Acta Neuropathol; 2021 Jul; 142(1):117-137. PubMed ID: 33913039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19.
    Fiscon G; Conte F; Farina L; Paci P
    PLoS Comput Biol; 2021 Feb; 17(2):e1008686. PubMed ID: 33544720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges in diagnosis and management of delirium in Lewy body disease.
    Richardson S; Lawson RA; Price A; Taylor JP
    Acta Psychiatr Scand; 2023 May; 147(5):475-480. PubMed ID: 36281704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Lewy body dementia and Parkinson disease dementia].
    Meyniel C; Damier P
    Presse Med; 2007 Oct; 36(10 Pt 2):1485-90. PubMed ID: 17572053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of antidepressant therapy on a patient with progressive supranuclear palsy accompanied by depression, anxiety and fluctuating dementia.
    Zhao Z; Mei X; Shi L; Zheng C
    Asian J Psychiatr; 2023 Feb; 80():103418. PubMed ID: 36565660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trials of dementia with Lewy bodies and Parkinson's disease dementia.
    Aarsland D; Ballard C; Rongve A; Broadstock M; Svenningsson P
    Curr Neurol Neurosci Rep; 2012 Oct; 12(5):492-501. PubMed ID: 22806065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.